Live
FierceBiotechADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal programFierceBiotechLilly moves deeper into Alzheimer’s research with AlzeCure licensing dealFierceBiotechCancer biotech Parabilis ups IPO plans to potentially record-setting $637MEndpoints NewsEndpoints Women in Biopharma: Nominate for 2026Lonza NewsAmMax Bio licenses ADC technology from Lonza - The Pharma LetterFDA News ReleasesFDA Expands Sunscreen Options for the First Time in 20 YearsEndpoints NewsPharma and biotech salaries: Top-paying companies of 2025FierceBiotechRoche sticks with €600M diagnostics investment in Germany but warns of future risk10x Genomics Blog10x Genomics (TXG) Expands Capabilities with Proteintech Genomics Acquisition - GuruFocusFierceBiotechCeQur nabs $100M series E to fuel insulin patch commercialization10x Genomics News10x Genomics acquires Proteintech Genomics division - Investing.comPharmaVoiceWith a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its mark
eLife 23 janv. 2026

Computational modelling identifies key determinants of subregion-specific dopamine dynamics in the striatum

Computational modelling identifies key determinants of subregion-specific dopamine dynamics in the striatum

Original
Contenu indisponible. Consultez la source originale.